Yoshikawa M, Tsujii T, Fukui H, Yamao J, Tsukamoto N, Nishimura N, Kyo M, Takaya A, Tsujii H, Nakano H
Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan.
Gastroenterol Jpn. 1991 Jul;26 Suppl 3:202-5. doi: 10.1007/BF02779299.
Antibodies against hepatitis C (HCV) in 512 patients were measured by an enzyme immunoassay (Ortho-HCV ELISA). The frequency of anti-HCV was 80%, 86%, 85% in nonB (NB) chronic hepatitis (CH), cirrhosis (LC), hepatocellular carcinoma (HCC), respectively; 70%, 90% in alcoholic (AL) LC, HCC; 15%, 33%, 58% in hepatitis B (HB) CH, LC, HCC, respectively. Anti-HCV positive cirrhotics had a shorter survival time and earlier development of HCC than anti-HCV negative cirrhotics. The findings suggest that HCV is a major cause of NB chronic liver diseases and may play a pathogenetic role in AL and HB liver diseases.
采用酶免疫分析法（Ortho-HCV ELISA）检测了512例患者的丙型肝炎病毒（HCV）抗体。抗-HCV在非B型（NB）慢性肝炎（CH）、肝硬化（LC）、肝细胞癌（HCC）中的出现频率分别为80%、86%、85%；在酒精性（AL）LC、HCC中分别为70%、90%；在乙型肝炎（HB）CH、LC、HCC中分别为15%、33%、58%。抗-HCV阳性的肝硬化患者比抗-HCV阴性的肝硬化患者生存时间更短，HCC发生更早。这些发现表明，HCV是NB慢性肝病的主要病因，可能在AL和HB肝病的发病机制中起作用。
